Moving forward, the results of the phase 3 SURPASS clinical trial program demonstrated that tirzepatide was as effective and safe as other anti-diabetic agents, such as semaglutide and dulaglutide (SURPASS-2) (SURPASS J-mono), long-acting insulin analogs (degludec and glargine) (SURPASS-3,4), and placebo (SURPASS-1) (SURPASS-5), in managing T2DM diabetes [65,66,67,68,69]
The mechanism involves clearance of senescent Leydig cells that secrete pro-inflammatory SASP factors (IL-1, IL-6, TGF-) which impair testosterone production in neighboring healthy cells
8,00025,000 per session Oral Liquid: Rs
Semisynthetic biosensors for mapping cellular concentrations of nicotinamide adenine dinucleotides